Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1401-1420 of 1,782 trials

HER2 Positive Esophageal Cancer: HERES Trial

We are studying whether adding trastuzumab to standard chemotherapy and immunotherapy helps patients with HER2 positive esophageal squamous cell carcinoma live longer without disease progression.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Bladder Cancer Treatment: BCG vs. BCG/EMDA-MMC

We are studying two treatment methods for high-risk non-muscle-invasive bladder cancer to see which is more effective and safer. This trial will help us understand the best approach to prevent disease progression.

Bladder Cancer6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsInternal MedicineUrology

Pediatric Hip Surgery: Tranexamic Acid Study

We are testing whether tranexamic acid can reduce blood loss during hip surgeries in children. This study aims to see if it helps improve recovery and reduces the need for blood transfusions.

Slipped Capital Femoral Epiphysis (SCFE)Legg-Calvé-Perthes Disease (LCPD)Neuromuscular ConditionsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyPediatrics

Metastatic Pancreatic Cancer: 5-FU with NALIRI or NALIRINOX

We are studying two new treatment combinations for patients with metastatic pancreatic ductal adenocarcinoma who have progressed after prior therapies. The aim is to see if these combinations improve survival and are safe to use.

Metastatic Pancreatic CancerEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Knee Osteoarthritis: Bovine vs. Marine Chondroitin Sulfate

We are comparing two types of chondroitin sulfate tablets to see if they help reduce pain and improve function in people with knee osteoarthritis. This study will also look at how these treatments affect quality of life and safety.

Knee Osteoarthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Gastric Cancer Treatment: GASTRICHIP Trial

We are comparing two surgical treatments for advanced gastric cancer to see if adding chemotherapy during surgery improves survival rates. This study involves patients with specific stages of gastric adenocarcinoma.

Stomach Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Stage IIIA/B NSCLC: New Immunotherapy and Chemotherapy Approach

We are studying a new treatment combining immunotherapy and chemotherapy for patients with resectable stage IIIA/B non-small cell lung cancer. The trial aims to see if this approach improves survival and quality of life compared to standard treatments.

Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Heart Health: Treatment for Frequent PVCs

We are studying whether treating asymptomatic patients with frequent PVCs can prevent future heart function problems. This trial compares treatment options to simple monitoring to see which is more effective.

Premature Ventricular Contractions (PVCs)>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyPediatrics

Eculizumab for Hypertensive Emergency-Associated Kidney Condition

We are studying whether Eculizumab can improve kidney function in patients with a severe kidney condition linked to high blood pressure. This trial will help us understand its effects on dialysis needs and overall health.

Atypical Hemolytic Uremic Syndrome (aHUS)1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Bariatric Surgery: Metformin for Diabetes Management

We are studying whether adding metformin to standard care helps people who had bariatric surgery stay diabetes-free longer. This trial focuses on former type 2 diabetes patients and their overall health and quality of life.

Type 2 Diabetes>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Glycerol Phenylbutyrate for Pyruvate Dehydrogenase Deficiency

We are studying whether Glycerol Phenylbutyrate can help reduce fatigue and improve quality of life for patients with Pyruvate Dehydrogenase Deficiency. The trial will also assess its safety and effects on neurodevelopmental symptoms.

Pyruvate Dehydrogenase Deficiency1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGastroenterologyNeurology

Sedation Study: Remimazolam vs. Midazolam for GI Endoscopy

We are comparing two sedation medications to see which one helps patients recover faster after upper GI endoscopy. We’ll also look at patient satisfaction and any side effects.

Healthy ParticipantsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Beta-Lactam Antibiotics: Precision Dosing in Critically Ill Children

We are studying a new dosing method for beta-lactam antibiotics in critically ill children to see if it helps them reach treatment goals faster than standard dosing. This may also help reduce their time in the hospital.

Systemic Infections>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Urothelial Cancer: DDR Gene Testing for Chemotherapy Response

We are studying whether changes in DDR genes can help predict how well patients with advanced urothelial cancer respond to platinum-based chemotherapy. This may lead to better treatment decisions for patients based on their genetic profile.

Metastatic or Locally Advanced Urothelial Cancer1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology